Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:49:53.186Z.
Calculation as of: 2026-10-06T19:49:53.186Z.
Quote observation: 2026-10-06T19:41:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76451fd983189bd376b55241b8a4b850ffcaa8def2b2c0e687122d8ae3ae7442
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Verrica Pharmaceuticals Inc.
Market Cap
$71.98M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$76.24M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $71.98M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.90M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.60M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $74.97M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.02M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $76.24M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.82M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.93M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.36M | N/A | 25.28x | 28.49x | 157.43x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
